Search PubMed⌕ Search

Biomedical subjects

S S Chatterjee

Publications and source records attributed to S S Chatterjee.

At least 73 records · Page 4Linked to original sources
PubMed1980

Long-term study of flunisolide treatment in perennial rhinitis with special reference to nasal mucosal histology and morphology.

Ten patients with allergic perennial rhinitis completed a 3-month course of reatment with flunisolide nasal spray. Biopsy of the nasal mucosa was carried out before the initiation of treatment and at the end of the treatment period. The flunisolilde was administered as a 0.025% solution twice daily at a total daily dose of 200 micrograms. No histological abnormalities which could have been attributed to the effects of the drug were found in the post-treatment biopsies. Comparison of the pre- and post-treatment histological features showed either that there had been no apparent changes or that there had been a reduction in the oedema and/or cellular infiltration which had been present initially. All except one patient improved clinically and in this case the pre-treatment nasal biopsy demonstrated features of atrophic rhinitis.

Adolescent↗
PubMed1980

Efficacy of nifedipine in the treatment of angina pectoris and chronic airways obstruction.

Twenty patients suffering from angina pectoris with co-existing fixed or labile airways obstruction, were administered fortnightly treatment periods of nifedipine or matching placebo over an 8-week period. Maintenance treatment for their airways obstruction continued throughout this period. Nifedipine was found to be an effective drug in controlling their angina, and did not have an adverse effect on the airways obstruction. Both systolic and diastolic BP was reduced over a 90-min period after administration of a single dose of nifedipine.

Adult↗
PubMed1980

A comparative trial of combination therapy in obstructive airways disease.

Eleven patients suffering from chronic reversible airways obstruction completed a comparative crossover trial of two combinations of a controlled-release aminophylline formulation and inhaled salbutamol, and two combinations of oral and inhaled salbutamol. Assessment was by FEV1, which was measured at the end of each 2-week treatment period. The highest mean FEV1 was recorded in patients using controlled-release aminophylline plus routine inhaled salbutamol. The only treatment which gave a significant (p < 0.05) increase over baseline was a combination of controlled-release aminophylline and inhaled salbutamol on demand. The combination of controlled-release aminophylline plus inhaled salbutamol on need was significantly more effective than the combination of oral salbutamol plus routinely inhaled salbutamol.

Adult↗
PubMed1979

Flunisolide--a new intranasal steroid for the treatment of allergic rhinitis.

A double-blind, cross-over comparison of flunisolide nasal spray and its inactive aqueous vehicle has been carried out in fifty patients suffering from perennial allergic rhinitis. Patients were randomly allocated to two groups; the first group (group I) received flunisolide for 3 weeks and then placebo for 3 weeks while the regimes were given in the reverse order to the second group (group II). Patients used two insufflations of 0.1 ml in each nostril twice daily. As the active spray was presented as a 0.025% solution of flunisolide, the total daily dosage was 200 microgram. Patients were assessed on admission and at the end of each 3 week period. The results show flunisolide to be significantly superior to placebo in relieving sneezing, nasal obstruction and postnasal drip, as well as improving the quality of sleep and everday life. At the end of the trial the preferences for treatment recorded by both doctors and patients were significantly in favour of the flunisolide spray. Side effects were minor and occurred during both placebo and active phases of the trial. A short Synacthen test performed at each visit showed no evidence of adrenal suppression.

Administration, Intranasal↗
PubMed1979

A comparison of controlled-release aminophylline (Phyllocontin Continus tablets) and sympathomimetic bronchodilators.

In a crossover trial on twenty-four patients with reversible airways obstruction the rise in FEV1 on Phyllocontin Continus tablets (15%) was comparable to that achieved with Alupent tablets (14%). The usage of inhaled salbutamol and frequency of attacks of wheeziness were both greater when the patients were taking Alupent tablets. In a second study the effect of Phyllocontin tablets and Ventolin tablets both in combination with inhaled Ventolin and alone were examined. It was found that on Phyllocontin tablets alone patients showed a similar improvement (22%) in FEV1 to Ventolin tablets alone (19%). When inhaled Ventolin was added to Phyllocontin tablets a further rise in FEV1 was seen but not when inhaled Ventolin was added to Ventolin tablets.

Albuterol↗
PubMed1979

Inhaled corticosteroid aerosols and candidiasis.

A three-month controlled study was performed to assess the cumulative incidence of oral Candida carriage and thrush in patients starting to take betamethasone valerate aerosol (800 microgram/day) for control of their asthma. Four of 41 patients on the corticosteroid aerosol developed thrush compared with none of 40 in the control group. However, the number of cumulative saliva culture positives for C. albicans rose by a similar amount (approximately 20%) in each group. A simple mouthwash procedure was shown to have no prophylactic benefit in the aerosol group. Oral candidiasis was not, however, clinically important.

Administration, Oral↗
PubMed1978

Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction.

1 The effects of atenolol (50 mg and 100 mg) and oxprenolol (80 mg) on respiratory function were studied in ten patients with angina pectoris or hypertension complicated by chronic airways obstruction. 2 In patients with "fixed" airways obstruction, neither atenolol nor exprenolol significantly affected airways resistance. 3 In patients with "labile" airways obstruction, atenolol did not produce a significant increase in airways obstruction, whereas oxprenolol did. 4 Following isoprenaline challenge (1500 microgram by inhalation), atenolol permitted full bronchodilatation, whereas oxprenolol almost completely blocked the action of isoprenaline. 5 Partial agonist activity appears to be of less clinical importance than cardioselectivity.

Adult↗
PubMed1978

Beta-blockers and asthma.

In a single-blind, randomised, crossover study in 10 asthmatic patients, the effects of approximately equipotent oral doses of 3 cardioselective beta-blockers-atenolol (100 mg), metoprolol (100 mg), and acebutolol (300 mg)-and 4 non-cardioselective beta-blockers-proranolol (100 mg), oxprenolol (100 mg), pindolol (5 mg), and timolol (10 mg) upon FEV1 were compared. All drugs, except pindolol, produced a significant reduction in standing pulse rate and prevented an increase in heart rate after inhaled isoprenaline (1500 microgram). All drugs caused a fall in FEV1 but only atenolol did not differ significantly from placebo in this respect. The bronchodilator response to inhaled isoprenaline was blocked by the 4 non-cardioselective drugs; the 3 cardioselective agents permitted some bronchodilatation, but only atenolol did not differ from placebo.

Adolescent↗
PubMed1977

A comparison of ipratropium bromide, deptropine citrate and placebo in asthma and chronic bronchitis.

A new anticholinergic aerosol, ipratropium bromide, was compared in a double-blind cross-over trial with an established preparation, deptropine citrate, and placebo in 16 patients with defined asthma or chronic bronchitis. Ipratropium bromide produced a significantly greater and more rapid bronchodilation than did deptropine citrate or placebo in the doses used, and its effect was slightly greater in the asthmatic than in the chronic bronchitic group. No unwanted effects on secretion were seen with ipratropium bromide.

Adult↗
PubMed1977

Experience with the use of a corticosteroid aerosol.

1. In 48 patients with chronic asthma who had been receiving treatment with beclomethasone dipropionate aerosol (BDA) at a daily dose of 400 microgram for several years, observations were made on the effect of increasing the dose to 800 microgram daily for 6 months. 2. There was subjective improvement in 37 of the 48 patients, but the only objective evidence of improvement was a slight reduction in airways resistance. 3. The higher dose of BDA did not produce impairment of pituitary-adrenal function or an increase in the incidence of oropharyngeal candidiasis.

Adolescent↗
PubMed1976

Effect of anti-inflammatory agent on L-glutamine-D-fructose-6-phosphate transaminase.

The enzyme L-glutamineD-fructose-6-phosphate aminotransferase (EC 2.6.1.16) was isolated, partially characterized, and purified from the gastric mucosa of dogs. A new method, using 14C-fructose-6-phosphate, has been developed for the estimation of the enzyme activity. Several classes of standard anti-inflammatory agents including acetyl-salicylic acid, salicylic acid, flufenamic acid, phenyl-butazone, indometacin, mefenamic acid, oxyphenyl-butazone, antipyrine, aminophenazone, allopurinol, cortisol, and dimethylsulfoxide (DMSO) were found to be inhibitors of this enzyme. The property of inhibition of this amino-transferase could, thus, be used as a rapid in vitro test method for the primary screening of potential anti-inflammatory agents.

Animals↗
PubMed1976

Influence of anti-inflammatory agents on rat liver mitochondrial ATPase.

Several classes of anti-inflammatory agents including acetyl-salicylic acid, salicylic acid, flufenamic acid, phenyl-butazone, indometacin, oxyphenyl-butazone, and mefenamic acid were found to be inhibitors of rat liver mitochondrial ATPase in both intact and freeze-ruptured mitochondria. The freeze-ruptured mitochondrial ATPase was found to be Mg2+- and ATP-concentration dependent. The standard uncoupler, 2,4-dinitrophenol, not possessing anti-inflammatory activity, activates the enzyme in both preparations. A number of compounds of various structural classes possessing no anti-inflammatory property in vivo were found to have no inhibitory effect on the enzyme. This inhibition of ATPase by anti-inflammatory agents could be used as an in vitro test method for the primary screening of potential anti-inflammatory agents.

Adenosine Triphosphatases↗